Shipitsin Michail, Polyak Kornelia
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Lab Invest. 2008 May;88(5):459-63. doi: 10.1038/labinvest.2008.14. Epub 2008 Mar 31.
Cancer is a disease of genes. Inherited or somatic alterations in genes are what make a normal cell ignore growth-controlling signals and form a tumor that eventually leads to the destruction of the organism. Based on accumulated knowledge on the genetic composition of cancer cells, the clonal evolution model of tumorigenesis was established, which explains multiple aspects of human disease and clinical observations. However, the recently popularized cancer stem cell hypothesis questions that all or most tumor cells can participate in tumor evolution and restricts this property to a subset of them defined as 'cancer stem cells' due to their stem cell-like characteristics. Enthusiasm surrounding this area of investigation and its presumed clinical implications led to a spurt of studies in various cancer types and model systems. Rigorous study design and critical data interpretation have to be employed to test the scientific and clinical relevance of the cancer stem cell hypothesis and its relationship to the clonal evolution model.
癌症是一种基因疾病。基因的遗传或体细胞改变使得正常细胞无视生长控制信号,形成肿瘤,最终导致机体的破坏。基于对癌细胞基因组成的积累知识,建立了肿瘤发生的克隆进化模型,该模型解释了人类疾病和临床观察的多个方面。然而,最近流行的癌症干细胞假说对所有或大多数肿瘤细胞都能参与肿瘤进化提出了质疑,并将这种特性限制在一部分因其具有干细胞样特征而被定义为“癌症干细胞”的细胞中。围绕这一研究领域及其假定的临床意义的热情引发了对各种癌症类型和模型系统的大量研究。必须采用严谨的研究设计和批判性的数据解释来检验癌症干细胞假说的科学和临床相关性及其与克隆进化模型的关系。